IL-18 has been shown to increase the production and deposition of Aβ in the brains of AD mice by promoting the expression of APP and β-site APP cleaving enzyme 1 (BACE1) that may contribute to the development of AD pathology by promoting Aβ accumulation. Here, IL18 is linked to Alzheimer disease.